 |
|
New treatment strategy offers hope to RA patients who failed all other therapies
June 12, 2009Rheumatoid arthritis (RA) patients who failed to respond to initial treatment with rituximab (RTX) (a chimeric monoclonal antibody against the protein CD20) can still be successfully re-treated with a second course of RTX after six months, according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark.
In the study, 72% of RA patients who did not respond to initial treatment with RTX achieved improved disease activity scores (DAS28) and EULAR responses when re-treated with RTX after six months. In some cases the responses were dramatic, with patients achieving complete remission for a year or longer.
Although the exact cause of rheumatoid arthritis is not complete understood, it is believed to involve B cells (part of the immune system) that become abnormal and cause the immune system to attack the joints. Rituximab works by killing B cells, removing the cause of the inflammation. B cells are gradually replaced over the next 6 to 12 months by new cells from the bone marrow. Rituximab is effective in approximately two thirds to three quarters of patients treated, however in some patients it is ineffective. Under current licensing rituximab is generally used only when all other treatments (such as methotrexate or anti-TNF agents) have failed. This means that patients that fail to respond to rituximab usually have no other treatment available to them. Although new drugs are being developed for RA, this study demonstrates why rituximab treatment fails in some patients, and how it can be used more effectively to treat patients with the worst disease.
The study used a technique called highly sensitive flow cytometry that can accurately measure the very small numbers of B cells that remain in the system after treatment with rituximab. Initial studies with rituximab in RA seemed to show that all B cells were completely removed in all patients, even those that failed to show an improvement in symptoms and signs of arthritis after treatment. Highly sensitive flow cytometry shows that B cells are not always completely removed, and almost all patients that fail to improve after rituximab have incomplete B cell depletion. In addition, patients in whom B cell depletion is incomplete have higher numbers of certain B cells (preplasma and memory B cells) before treatment.
In the study, 104 patients (with complete data) were treated with rituximab and depletion assessed using highly sensitive flow cytometry. 90% of patients who did not respond clinically to treatment had incomplete B cell depletion. Non-response could also be predicted by higher baseline levels of memory B cells (p= 0.027) and preplasma cells (p= 0.006). 25 patients who had failed to respond to an initial treatment with rituximab were retreated six months later. At this stage B cells had not yet recovered to pre-treatment levels. Re-treating with a second course of rituximab resulted in greater B cell depletion, with 48% now achieving complete depletion (p = 0.02). 72% of these patients then responded clinically, as defined by a moderate or better EULAR response. 32% had a good response and 16% were in remission. A significant improvement was observed in DAS28* (p < 0.001) and all its components of DAS28.
Dr Edward Vital of Leeds Institute of Molecular Medicine, University of Leeds, UK, who led the study, said: "Although rituximab can be effective in RA, around a third of patients fail to achieve an adequate response the first time they are treated. Our study has shown that re-treating patients at a specific stage can enhance clinical responses to a level equal to those who fully respond to the RTX course at first administration. This provides hope for patients who are classified as non-responders and would normally have limited other treatment options. The next question is whether patients who have predictors of poor response could be treated more intensively from the outset, for example with a different dose of rituximab."
European League Against Rheumatism
The study used a technique called highly sensitive flow cytometry that can accurately measure the very small numbers of B cells that remain in the system after treatment with rituximab. Initial studies with rituximab in RA seemed to show that all B cells were completely removed in all patients, even those that failed to show an improvement in symptoms and signs of arthritis after treatment. Highly sensitive flow cytometry shows that B cells are not always completely removed, and almost all patients that fail to improve after rituximab have incomplete B cell depletion. In addition, patients in whom B cell depletion is incomplete have higher numbers of certain B cells (preplasma and memory B cells) before treatment.
In the study, 104 patients (with complete data) were treated with rituximab and depletion assessed using highly sensitive flow cytometry. 90% of patients who did not respond clinically to treatment had incomplete B cell depletion. Non-response could also be predicted by higher baseline levels of memory B cells (p= 0.027) and preplasma cells (p= 0.006). 25 patients who had failed to respond to an initial treatment with rituximab were retreated six months later. At this stage B cells had not yet recovered to pre-treatment levels. Re-treating with a second course of rituximab resulted in greater B cell depletion, with 48% now achieving complete depletion (p = 0.02). 72% of these patients then responded clinically, as defined by a moderate or better EULAR response. 32% had a good response and 16% were in remission. A significant improvement was observed in DAS28* (p < 0.001) and all its components of DAS28.
Dr Edward Vital of Leeds Institute of Molecular Medicine, University of Leeds, UK, who led the study, said: "Although rituximab can be effective in RA, around a third of patients fail to achieve an adequate response the first time they are treated. Our study has shown that re-treating patients at a specific stage can enhance clinical responses to a level equal to those who fully respond to the RTX course at first administration. This provides hope for patients who are classified as non-responders and would normally have limited other treatment options. The next question is whether patients who have predictors of poor response could be treated more intensively from the outset, for example with a different dose of rituximab."
European League Against Rheumatism
Arthritis Current Events and Arthritis News RSSCommon Pain Relievers May Dilute Power of Flu Shots
With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system.
Mending meniscals in children, improving diagnosis and recovery
The meniscus is a rubber-like, crescent moon-shaped cartilage cushion that sits between the leg and thigh bone. Each knee has two menisci: one on the inside of the knee joint and one on the outside.
Study finds link between childhood physical abuse and arthritis
Adults who had experienced physical abuse as children have 56 per cent higher odds of osteoarthritis compared to those who have not been abused, according to a new study by University of Toronto researchers.
Pain thresholds linked to inflammation and sleep problems in arthritis patients
Despite recent advances in anti-inflammatory therapy, many rheumatoid arthritis (RA) patients continue to suffer from pain.
URI research couple's method targets cancerous tumors
Two University of Rhode Island associate professors, biophysicists Yana Reshetnyak and Oleg Andreev, have discovered a technology that can detect cancerous tumors and deliver treatment to them without the harming the healthy cells surrounding them, thereby significantly reducing side effects.
Changing behavior helps patients take medication as prescribed
Taking medication as the doctor prescribes is crucial to improving health. However, 26 to 59 percent of older adults do not adhere to instructions, according to a 2003 study published in Drugs and Aging.
Extra care for outwardly healthy workers costs companies millions annually
Someone healthy enough to work could still cost an employer more than $4,000 annually in unnecessary health care costs.
New therapy for vasculitis will help patients avoid infertility and cancer
Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy.
Stanford study identifies cellular mechanism that causes lupuslike symptoms in mice
Macrophages, the scavenger cells of the body's immune system, are responsible for disposing of dying cells. Stanford University School of Medicine researchers have identified one pathway in this important process in mice that, if disrupted, causes a lupuslike autoimmune disease.
Trial raises doubts over alternative pain therapy for arthritis
Copper bracelets and magnetic wrist straps are ineffective in relieving arthritis pain, according to a new study led by a University of York academic.
More Arthritis Current Events and Arthritis News Articles
 |
Conquering Arthritis: What Doctors Don't Tell You Because They Don't Know by Barbara D Allan (Author) This book is newly revised and updated with important updates that make healing from arthritis even easier and quicker. It has been used with great success by many people with rheumatoid arthritis, osteoarthritis, and other forms of arthritis, to heal themselves. It provides practical, detailed information that is critical for the successful healing of arthritis, but that has never before been collected in one place. The information is organized into a well-researched, easy-to-follow plan for getting well again and includes case histories of people with dramatic and lasting recoveries. It focuses not just on coping with the symptoms of arthritis, but on correcting its underlying causes using proven alternative medicine and pain management techniques. ... |
 |
Imak Arthritis Gloves Medium (Pack of 2) by IMAK The IMAK Arthritis Gloves help relieve aches, pains and stiffness associated with Arthritis of the hands. The unique design provides mild compression, offers warmth and helps increase circulation and promote healing. The Arthritis Gloves are made of soft |
 |
The Arthritis Cure, Revised and Updated: The Medical Miracle That Can Halt, Reverse, And May Even Cure Osteoarthritis by Jason Theodosakis (Author), Sheila Buff (Author), Barry Fox (Author) Since its original publication in 1996, The Arthritis Cure has swept the nation, providing amazing relief for the millions who suffer chronic arthritis pain. By outlining a nine-point program that includes a new effective supplement, ASU, The Arthritis Cure Revised Edition describes a program that can halt, reverse, and possibly even cure degenerative osteoarthritis. Based on the most recent and cutting-edge medical research, this invaluable resource promises readers: --The latest research indicating that prescription arthritis drugs are not only expensive but can also be dangerous--they can raise blood pressure and damage the kidneys. --New studies supporting the use of glucosamine and chondroitin to treat arthritic symptoms. --Dr. Theodosaki's ratings of the current... |
 |
Arthritis Gloves - Medium - 1 pair by Imak IMAKs® Arthritis Gloves are designed to help relieve aches, pains, and stiffness associated with arthritis of the hands. The unique design of the IMAK Arthritis Gloves provides mild compression for warmth and helps increase circulation, which ultimately reduces pain and promotes healing. The Arthritis Gloves are made of soft, breathable cotton Lycra®, meaning they are comfortable enough to wear all day and night. The open fingertips allow you complete freedom to feel, touch and grip, so you can perform daily tasks without issue. |
 |
The New Arthritis Breakthrough: The Only Medical Therapy Clinically Proven to Produce Long-term Improvement and Remission of RA, Lupus, Juvenile RS, Fibromyalgia, ... & Other Inflammatory Forms of Arthritis by Henry Scammell (Author) "...can be miraculous for rheumatoid arthritis sufferers."-- Health & Healing, Tomorrow's Medicine Today |
 |
Arthritis Advantage for Arthritis Dietary Supplement Caplets, 32-Count Box (Pack of 2) by Arthritis Advantage APR Arthritis Advantage for relief of arthritis symptoms |
 |
Arthritis, What Exercises Work: Breakthrough Relief For The Rest Of Your Life, Even After Drugs & Surgery Have Failed by Dava Sobel (Author), Arthur C. Klein (Author) What is the most powerful arthritis treatment ever developed to help restore you to a healthy, pain-free, and vigorous life--for the rest of your life? It's the very same breakthrough that has: --Helped more arthritis sufferers than drugs, surgery, or any other treatment--without dangerous side effects. --Been widely prescribed by medical doctors and other health practitioners. The answer? Exercise. Here are the right exercises for your kind of arthritis, pain-level, age, occupation, and hobbies. And they're the most effective exercises for arthritis available anywhere--rated "best" by arthritis sufferers themselves in an unprecedented nationwide survey...supported by medical doctors...and backed by the latest research. only this book has them. Let... |
 |
Cosamin DS Joint Health Supplement, Capsules, 210-Count Bottle by Cosamin DS Glucosamine (FCHG49), Chondroitin Sulfate (TRH122). Exclusive formula. Protect your cartilage with the only brand proven to reduce joint pain. (These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.) Easy to swallow. Exclusive trademarked ingredients. The Orthopedic Surgeon and Rheumatologist No. 1 recommended brand. Safe and Economical: There are no known interactions or serious side effects with CosaminDS. Exclusive ingredients allows reduction in the number of capsules taken over time. CosaminDS is Recommended by Doctors and Pharmacists for Joint Health: The only brand proven effective in controlled, published US studies to reduce joint pain. Shown in laboratory tests to protect... |
 |
How to Eat Away Arthritis: Gain Relief from the Pain and Discomfort of Arthritis Through Nature's Remedies by Laurie M. Aesoph (Author) This revised and expanded edition of the perennially popular self-help book details how arthritis sufferers can improve their conditions with the foods they eat. Using the simple dietary procedures described in this book, readers can reverse some cases of osteoarthritis or rheumatoid arthritis without expensive drugs or equipment. |
 |
Duro-Med Arthritis Natural Pain Relief Microwavable Therabead Moist Heat Standard Pack with Cover, 9 X 12 by Duro-Med Duro-Med Industries' amazing Therabeads microwaveable heat products represent a major breakthrough in moist heat therapy. TheraBeads delivers moist heat safely and effectively. By utilizing the convenience of a microwave oven, TheraBeads provide therapeutic moist heat at the correct temperature levels needed for effective therapy. Full 9"x12" size is ideal for most parts of the body including shoulders, knees and back. Deliver uniform moist heat to help relieve soreness and stiffness. With proper care Therabeads can be used indefinately. Includes wrap cover. |
| © 2009 BrightSurf.com |